GlycanAge for Healthcare Providers, Functional Medicine Clinics & Corporate Wellness Programs

Most functional medicine clinics can already tell a patient their cholesterol, their HbA1c, their hormone panel. What they usually cannot tell that patient is whether their immune system is aging faster than it should, or whether the HRT, the peptide protocol, or the lifestyle overhaul actually changed anything at the biological level. That gap between "we treated you" and "we can prove it worked" is where most preventive practices lose patients, and it's exactly the gap that biological age testing for clinics is built to close.

GlycanAge is a blood-based biomarker that measures biological age by analysing IgG glycosylation, the pattern of complex sugars (called glycans) attached to a class of antibody called Immunoglobulin G. Unlike DNA, which reveals fixed genetic potential, biological age measured this way is dynamic and something a patient can actually change. For clinics already blending aesthetics, hormone therapy, peptides, and longevity coaching, that distinction is the difference between offering a treatment and proving a result.

What Is GlycanAge, and Why Does It Matter for Preventive Practice?

What GlycanAge Measures

GlycanAge is a simple blood test that reveals biological age by measuring changes in immune system function and inflammation. Every cell in the body is coated in glycans, complex sugar structures that sit on the surface of proteins and govern how those proteins function and communicate. Most proteins in the body are glycoproteins, meaning they carry these sugar chains, and without them the protein does not work the way it is supposed to. IgG glycosylation, the specific sugar pattern on antibodies, shifts measurably with chronic inflammation, and that shift is what GlycanAge captures. This IgG-glycan-based approach to measuring biological age was first validated in a population study of over 5,000 individuals, which found that glycan patterns explained more variance in age than markers like telomere length.

Why It Matters for Preventive Practice

Patients are already paying for how they look on the outside: skincare, supplements, aesthetic procedures. Beneath that surface, biological aging is still being driven by inflammation, stress, lifestyle, and hormones. GlycanAge gives a way to bring that invisible layer into the conversation, and to track it over time rather than describing it in the abstract.

For a clinic, that reframes the offering. Instead of selling a single aesthetic or hormonal intervention, you can start the conversation around longevity by linking outer beauty with internal health, reveal chronic inflammation early, often before symptoms appear, and identify the right intervention on time. It moves the conversation beyond routine markers like cholesterol, toward a proactive view of how a patient is aging from the inside.

"There's no single biomarker that can function for everything, but glycans are predictive, they're responsive, they're stable. They are such a great indicator of inflammation and a very, very good biomarker of aging."

— Dr. Joseph Raffaele, MD, Founder, Raffaele Medical, New York City

How Is GlycanAge Different From Epigenetic Clocks, DNA Tests, and Generic Blood Panels?

Clinics evaluating a biological age biomarker are usually comparing three categories: epigenetic (DNA methylation) clocks, one-off genetic/DNA tests, and standard blood chemistry panels. GlycanAge sits apart from all three in a specific way that matters clinically.

Epigenetic clocks estimate age from DNA methylation patterns. They're informative for population-level research, but methylation changes slowly and reflects cumulative, longer-term biology, which makes short-interval retesting (the kind a clinic needs to validate a 3-to-12-month protocol) less practical as a routine tool.

DNA tests reveal fixed genetic potential — predispositions that don't change. They're useful for risk stratification, but they can't show whether this quarter's HRT titration, peptide protocol, or lifestyle change is actually working, because the underlying DNA doesn't move in response to treatment.

Generic blood panels (lipids, HbA1c, standard hormone levels) capture a snapshot that can fluctuate hour to hour and day to day. They don't carry a dedicated aging or inflammation signal the way a biomarker purpose-built to track IgG glycosylation does.

GlycanAge's role is to sit on top of all three, not replace them, as the layer that answers the one question none of them are built to answer: is the intervention changing the patient's biology, and how quickly?

How GlycanAge Fits Into an Existing Clinical Workflow

GlycanAge is designed to sit alongside the panels a practice already runs, not replace them. The test itself is a finger-prick blood spot sample, simple enough to be collected in-clinic or shipped directly to the patient, and returned to the lab for analysis. Every partner starter pack includes the test kits, a detailed report with recommended next steps, and educational resources with one-on-one results interpretation sessions. Starter packs are priced per partnership tier — reach out to the GlycanAge partnerships team for current pricing and shipping timelines for your region. That interpretation layer matters clinically: a biomarker result is only as useful as the conversation that follows it, and GlycanAge is built to hand a practitioner that conversation, not just a number.

Baselining Before Intervention

The most direct clinical use case is baselining a patient before starting a protocol, whether that protocol is hormone replacement therapy, a peptide regimen, or a structured lifestyle change. Many clinicians and partners run various protocols, but to know whether a protocol is actually working for a given patient, you typically need a personalised, objective test, and that is what GlycanAge offers. A pre-intervention result establishes the patient's starting biological age and their glycan index pattern, giving both clinician and patient a fixed point to retest against.

Retesting to Validate the Protocol

Retesting is where GlycanAge earns its place in the workflow, and the right interval depends on what the practice changed:

• Pharmaceutical and HRT-based protocols (hormone titration, peptide regimens): glycan shifts are typically measurable within 3–4 months, so retesting in this window allows for early assessment and protocol adjustment.

• Lifestyle-based protocols (nutrition, exercise, stress management, sleep): glycan shifts occur more gradually, and 6–12 months is the window that captures a genuine, sustained trend rather than noise.

This matters most in the interventions functional medicine and longevity practices already run: HRT titration for perimenopausal and menopausal patients, peptide and hormone protocols in longevity clinics, and structured nutrition or stress-reduction programmes in executive health work. The gradual, diet-driven end of that range is well supported: one intervention study tracking 1,850 IgG glycome samples found that even modest weight loss shifted glycosylation toward a younger biological age profile over several months, with the effect building further with sustained change. In each case, the same underlying clinical problem exists: the practitioner is making a change and needs an objective signal to know if it is working before waiting for symptoms, or the absence of symptoms, to tell the story.

"We have to start thinking about our health while we're still healthy, and start checking the biomarkers that change well before we become ill."

— Prof. Gordan Lauc, Professor of Biochemistry and Molecular Biology, University of Zagreb, and Co-Founder & Chief Scientific Officer, GlycanAge

Motivating the Patient Through Objective Change

Prevention depends on behaviour change, and behaviour change is largely psychological, driven by motivation as much as by clinical instruction. Having an objective tool a patient can see and measure, to understand whether something is working, is what re-engages that patient and keeps them motivated. That is a clinical utility point as much as a commercial one: a patient who sees their biological age move in response to a protocol they committed to is a patient who trusts the practice, follows through on the plan, and returns for the next test.

Retesting Cadence and Patient Retention

Why the Cadence Matters Commercially

Encouraging long-term engagement through retesting builds trust and boosts patient adherence. This is the structural advantage GlycanAge brings to a practice's economics: it creates a natural, clinically justified reason for a patient to come back — at 3–4 months for pharmaceutical or HRT protocols, or 6–12 months for lifestyle-driven ones, rather than leaving the relationship to lapse after a single course of treatment.

For a practice already running aesthetic procedures, hormone therapy, or IV and wellness protocols, that retest cadence turns a one-off transaction into a longitudinal care relationship. The patient is not just returning for another treatment; they are returning to see whether the treatment worked at a biological level, and that framing changes how the practice is perceived. It shifts the positioning from a menu of services to a longevity programme with a measurable outcome attached.

This also gives a practice a defensible answer to a question more patients are starting to ask: how do you know this is working? A generic blood panel captures a snapshot that fluctuates hour to hour and day to day; it does not carry a dedicated aging signal the way a dynamic biomarker built specifically to track chronic inflammation does. Positioning GlycanAge as the additional layer that sits on top of standard blood work, rather than a replacement for it, is the most direct way to explain its role to a patient who has already had labs drawn elsewhere.

Proof in Practice

Across GlycanAge's existing partner network, this framing already holds up in practice. One example: a healthy 46-year-old man working with Dr. Joseph Raffaele, founder of PhysioAge, saw no gap between his biological and chronological age at baseline, but his testosterone and estradiol levels were below optimal. After starting HRT and retesting over time, his biological age dropped by 20 years — a result that came from retesting the same patient against his own baseline, not from a single snapshot.

Practical Implementation: Bringing GlycanAge Into Your Practice

Starter Pack and Onboarding

Onboarding as a GlycanAge partner is designed to get practice from sign-up to the first patient test with minimal friction. In the first stage of onboarding, new partners are walked through what the partnership means, what the test is, and how to use it in practice. The starter pack itself is built around three components: the finger-prick test kits, delivered either to the practice or directly to the patient; a detailed patient report with guidance on recommended next steps; and educational resources paired with one-on-one results interpretation sessions. Ad hoc sales and marketing support is also included for practices building a longevity offering around the test.

Three Starting Points for Clinical Use

For a practitioner deciding where GlycanAge fits first, three starting points cover most of the clinical use cases already active in partner clinics:

• Baseline every patient starting a hormone, peptide, or structured lifestyle protocol, so there is a fixed reference point before the intervention begins.

• Retest at 3–4 months for pharmaceutical/HRT protocols, or 6–12 months for lifestyle-based ones, aligned to whatever cadence you already use for follow-up appointments or protocol reviews, so the result lands inside a conversation you are already having with the patient.

• Use the one-on-one interpretation session, included with every test, as the moment to walk the patient through their glycan index pattern and connect it back to the protocol you put them on, rather than treating the report as a document to hand over unexplained.

That last point is where the "objective referee" framing does real clinical work. A practitioner is not asking the patient to trust the treatment on faith, and the practice is not the only voice validating its own protocol. The biomarker sits outside the intervention, measuring whether the biology actually shifted, which gives both the clinician and the patient a shared, independent reference point.

Practices already running aesthetic interventions have a particularly natural entry point here, because their patients are already primed to invest in how they look and are aging.

Where This Leaves Your Practice

Preventive care lives or dies on proof, not intention. A practice that can show a patient a biological age reading before an HRT protocol, and a lower one after, is offering something a supplement recommendation or a single aesthetic procedure cannot. It's a measurable, repeatable signal that the intervention worked at the level of immune function and inflammation, not just at the level of symptoms or appearance. That signal is what turns a single visit into a longitudinal relationship, and a longitudinal relationship into the retention every longevity-focused practice is trying to build.

GlycanAge was developed with input from institutions including King's College London, the University of Cambridge, Harvard Medical School, the University of Oxford, Johns Hopkins University, and Stanford University, and it is backed by more than 30 years of glycobiology research and over 300 published scientific papers. For a practice deciding which biomarker deserves a place in its protocol library, that research base is the difference between a wellness add-on and a credible clinical tool.

Frequently Asked Questions

What is GlycanAge, and how is it different from other biological age tests?

GlycanAge measures biological age by analysing IgG glycosylation — the sugar patterns attached to antibodies that shift with chronic inflammation and immune function. Unlike DNA-based tests, which reveal fixed genetic potential, glycan-based results are dynamic and change in response to treatment, which is what makes them useful for tracking whether an intervention is working.

How does GlycanAge fit alongside the panels my clinic already runs?

GlycanAge is designed to sit on top of existing blood work, not replace it. It adds a dedicated aging and inflammation signal that most standard panels don't carry, giving clinicians an additional layer for baselining and retesting patients through hormone, peptide, or lifestyle protocols.

How soon can I retest a patient after starting a new protocol?

It depends on the intervention type. Pharmaceutical and HRT-based protocols typically show measurable glycan shifts within 3–4 months. Lifestyle-based protocols, such as diet, exercise, stress management, move more gradually, and 6–12 months captures a more reliable, sustained trend.

What's included in a GlycanAge partner starter pack?

Every starter pack includes finger-prick test kits, a detailed patient report with recommended next steps, and educational resources with a one-on-one results interpretation session, alongside ad hoc sales and marketing support for practices building out a longevity offering.

Which patients benefit most from adding GlycanAge to an aesthetic or longevity practice?

Patients already investing in how they look and age, through skincare, aesthetic procedures, or hormone therapy, are typically primed to engage with a biological marker that shows what's happening beneath the surface.

Give your patients an objective way to see whether their protocol is working, not just whether it feels like it is.

Explore Partnership Options for Providers →

External Sources

• https://pmc.ncbi.nlm.nih.gov/articles/PMC4049143/ — Krištić J, Vučković F, Menni C, Klarić L, Keser T, Beceheli I, et al. Glycans are a novel biomarker of chronological and biological ages. J Gerontol A Biol Sci Med Sci. 2014 Jul;69(7):779-89.

• https://pmc.ncbi.nlm.nih.gov/articles/PMC8236401/ — Greto VL, Cvetko A, Štambuk T, Dempster NJ, Kifer D, Deriš H, et al. Extensive weight loss reduces glycan age by altering IgG N-glycosylation. Int J Obes (Lond). 2021 Jul;45(7):1521-31.